Search

The Australian Epithelial Research Program (WAERP) comprises of several parties, including our Chief Investigators, Compliance, Scientific and Clinical Teams, and our Student group.

The Scientific Advisory Committee's (SAC) role is to provide scientific direction and to ensure the objectives of WAERP are reflected in the research performed; SAC forms part of our governance structure.

Want to know how to be involved with WAERP? Or how long the project is running for? View our Frequently Asked Questions (FAQs) for answers to these questions and more.

COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.

In a world being urged to embrace renewable options, biodiesel fuels are increasingly being touted as a greener, cleaner choice than traditional diesel.

Culturally secure intervention to facilitate medical follow up for Aboriginal children, after being hospitalised with chest infections, have proven to improve long-term lung health outcomes.

A public health campaign to raise awareness about the dangers of chronic wet cough in Aboriginal children is helping to improve detection, diagnosis and management of the condition.

Structural and functional defects within the lungs of children with cystic fibrosis (CF) are detectable soon after birth and progress throughout preschool years often without overt clinical signs or symptoms. By school age, most children have structural changes such as bronchiectasis or gas trapping/hypoperfusion and lung function abnormalities that persist into later life. Despite improved survival, gains in forced expiratory volume in one second (FEV1) achieved across successive birth cohorts during childhood have plateaued, and rates of FEV1 decline in adolescence and adulthood have not slowed. This suggests that interventions aimed at preventing lung disease should be targeted to mild disease and commence in early life.

We tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.